This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results
Celcuity(US:CELC) The Motley Fool·2025-11-27 22:22One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.New York City-based Apis Capital Advisors disclosed a new position in Celcuity Inc. (CELC +1.28%), acquiring 776,000 shares valued at $38,334,400 as of September 30, according to an SEC filing submitted on November 14, 2025.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Apis Capital Advisors, LLC initiated a new position in Celcuity (CELC +1.28% ...